Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
Crossref DOI link: https://doi.org/10.1186/s40425-017-0281-y
Published Online: 2017-09-19
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wang, Victoria E.
Urisman, Anatoly
Albacker, Lee
Ali, Siraj
Miller, Vincent
Aggarwal, Rahul
Jablons, David
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation